Elabscience

Recombinant Human TNF-alpha/TNFA Protein (aa 77-233, His Tag)(Active)

Product Code:
 
PKSH033164
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Human
Regulatory Status:
 
RUO
Application:
 
Cell Culture
Shipping:
 
The product is shipped at ambient temperature. Upon receipt store it immediately at the storage temperature listed.
Storage:
 
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSH033164-20ug20ug£129.00
Quantity:
PKSH033164-100ug100ug£210.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
TNF-alpha;TNFA
Accession:
P01375
Activity:
Measure by its ability to induce cytotoxicity in L929 cells in the presence of actinomycin D. The ED50 for this effectis < 0.1 ng/mL. The specific activity of recombinant human TNF alpha is approximately 1x 107 IU/mg.
Background:
Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α; which binds to both murine TNF receptors. Based on these results; many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.
Calculated MW:
18.5 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
E.coli
Formulation:
Lyophilized from a 0.2 um filtered solution of 20mM PB;150mM NaCl;pH7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-6His
ObservedMW:
16 kDa
Purity:
> 95 % as determined by reducing SDS-PAGE.
Sequence:
Val77-Leu233
Target Synonym:
Tumor Necrosis Factor;Cachectin;TNF-Alpha;Tumor Necrosis Factor Ligand Superfamily Member 2;TNF-a;TNF;TNFA;TNFSF2
UNIProt ID:
P01375

Documents